In its updated clinical guideline on the management of MS in primary and secondary care, NICE advised that patients should not be offered the cannabis-derived oromucosal spray Sativex to treat spasticity or the oral treatment fampridine (Fampyra) to improve walking disability. NICE judged that neither option was cost-effective.
NICE has issued positive opinions on the oral MS treatments dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), and fingolimod (Gilenya) and parenteral alemtuzumab (Lemtrada).